• Je něco špatně v tomto záznamu ?

Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma

D. Fassmannová, F. Sedlák, J. Sedláček, I. Špička, K. Grantz Šašková,

. 2020 ; 12 (5) : . [pub] 20200425

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20019285

Grantová podpora
LQ1604 Ministerstvo Školství, Mládeže a Tělovýchovy
CZ.1.05/1.1.00/02.0109 Ministerstvo Školství, Mládeže a Tělovýchovy
1172119 Grantová Agentura, Univerzita Karlova

Proteasome inhibitors are the backbone of multiple myeloma therapy. However, disease progression or early relapse occur due to development of resistance to the therapy. One important cause of resistance to proteasome inhibition is the so-called bounce-back response, a recovery pathway driven by the TCF11/Nrf1 transcription factor, which activates proteasome gene re-synthesis upon impairment of the proteasome function. Thus, inhibiting this recovery pathway potentiates the cytotoxic effect of proteasome inhibitors and could benefit treatment outcomes. DDI2 protease, the 3D structure of which resembles the HIV protease, serves as the key player in TCF11/Nrf1 activation. Previous work found that some HIV protease inhibitors block DDI2 in cell-based experiments. Nelfinavir, an oral anti-HIV drug, inhibits the proteasome and/or pAKT pathway and has shown promise for treatment of relapsed/refractory multiple myeloma. Here, we describe how nelfinavir inhibits the TCF11/Nrf1-driven recovery pathway by a dual mode of action. Nelfinavir decreases the total protein level of TCF11/Nrf1 and inhibits TCF11/Nrf1 proteolytic processing, likely by interfering with the DDI2 protease, and therefore reduces the TCF11/Nrf1 protein level in the nucleus. We propose an overall mechanism that explains nelfinavir's effectiveness in the treatment of multiple myeloma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019285
003      
CZ-PrNML
005      
20201123123736.0
007      
ta
008      
201103s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12051065 $2 doi
035    __
$a (PubMed)32344880
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fassmannová, Dominika $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610 Prague, Czech Republic. Department of Genetics and Microbiology, Charles University, Viničná 5, 12843 Prague, Czech Republic. First Faculty of Medicine, Charles University, Kateřinská 32, 12108 Prague, Czech Republic.
245    10
$a Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma / $c D. Fassmannová, F. Sedlák, J. Sedláček, I. Špička, K. Grantz Šašková,
520    9_
$a Proteasome inhibitors are the backbone of multiple myeloma therapy. However, disease progression or early relapse occur due to development of resistance to the therapy. One important cause of resistance to proteasome inhibition is the so-called bounce-back response, a recovery pathway driven by the TCF11/Nrf1 transcription factor, which activates proteasome gene re-synthesis upon impairment of the proteasome function. Thus, inhibiting this recovery pathway potentiates the cytotoxic effect of proteasome inhibitors and could benefit treatment outcomes. DDI2 protease, the 3D structure of which resembles the HIV protease, serves as the key player in TCF11/Nrf1 activation. Previous work found that some HIV protease inhibitors block DDI2 in cell-based experiments. Nelfinavir, an oral anti-HIV drug, inhibits the proteasome and/or pAKT pathway and has shown promise for treatment of relapsed/refractory multiple myeloma. Here, we describe how nelfinavir inhibits the TCF11/Nrf1-driven recovery pathway by a dual mode of action. Nelfinavir decreases the total protein level of TCF11/Nrf1 and inhibits TCF11/Nrf1 proteolytic processing, likely by interfering with the DDI2 protease, and therefore reduces the TCF11/Nrf1 protein level in the nucleus. We propose an overall mechanism that explains nelfinavir's effectiveness in the treatment of multiple myeloma.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sedlák, František $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610 Prague, Czech Republic. Department of Genetics and Microbiology, Charles University, Viničná 5, 12843 Prague, Czech Republic. First Faculty of Medicine, Charles University, Kateřinská 32, 12108 Prague, Czech Republic. 1st Department Medicine-Department of Hematology, Charles University, U Nemocnice 2, 12808 Prague, Czech Republic.
700    1_
$a Sedláček, Jindřich $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610 Prague, Czech Republic. Department of Genetics and Microbiology, Charles University, Viničná 5, 12843 Prague, Czech Republic.
700    1_
$a Špička, Ivan $u First Faculty of Medicine, Charles University, Kateřinská 32, 12108 Prague, Czech Republic. 1st Department Medicine-Department of Hematology, Charles University, U Nemocnice 2, 12808 Prague, Czech Republic.
700    1_
$a Grantz Šašková, Klára $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610 Prague, Czech Republic. Department of Genetics and Microbiology, Charles University, Viničná 5, 12843 Prague, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 5 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32344880 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123123735 $b ABA008
999    __
$a ind $b bmc $g 1586063 $s 1109483
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 5 $e 20200425 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a LQ1604 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a CZ.1.05/1.1.00/02.0109 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a 1172119 $p Grantová Agentura, Univerzita Karlova
LZP    __
$a Pubmed-20201103
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace